Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Zaggia

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Endocrine|June 25, 2013
Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatmentGiuseppe Reimondo, Marta Bondanelli, Maria Rosaria Ambrosio, et al.
Endocrine-Related Cancer|April 23, 2017
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancerElisa Roca, Alfredo Berruti, Silviu Sbiera, et al.
Endocrine-Related Cancer|April 23, 2010
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II studyPaola Sperone, Anna Ferrero, Fulvia Daffara, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Endocrine|June 25, 2013
Growth hormone values after an oral glucose load do not add clinically useful information in patients with acromegaly on long-term somatostatin receptor ligand treatmentGiuseppe Reimondo, Marta Bondanelli, Maria Rosaria Ambrosio, et al.
Endocrine-Related Cancer|April 23, 2017
Topoisomerase 2α and thymidylate synthase expression in adrenocortical cancerElisa Roca, Alfredo Berruti, Silviu Sbiera, et al.
Endocrine-Related Cancer|April 23, 2010
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II studyPaola Sperone, Anna Ferrero, Fulvia Daffara, et al.
Pageof 2